EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Lessons Learned from the Development of the First FDA-Approved Gene Therapy Drug, Voretigene Neparvovec-rzyl

Jean Bennett, Albert M Maguire

Cold Spring Harbor Perspectives in Medicine · 2023-05 · 13 (5) · a041307

DOI: 10.1101/cshperspect.a041307 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cold Spring Harbor Perspectives in Medicine, online erschienen am 27.09.2022. Verfasst von Jean Bennett und 1 weiteren Autor:innen. Beteiligte Einrichtung: Scheie Eye Institute at the Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania 19104, USA jebennet@pennmedicine.upenn.edu. Hauptthemen laut MEDLINE: Retinal Dystrophies. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Retinal DystrophiesHumanscis-trans-IsomerasesGenetic VectorsGenetic Therapy

Substanzen

cis-trans-Isomerases

Autor:innen und Institutionen

  • Scheie Eye Institute at the Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania 19104, USA jebennet@pennmedicine.upenn.edu.
  • Center for Advanced Retinal and Ocular Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 19104, USA.
  • Scheie Eye Institute at the Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania 19104, USA.
  • Division of Ophthalmology at the Children's Hospital of Philadelphia of the Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania 19102, USA.

Zitieren

APA

Bennett, J., & Maguire, A. M. (2023). Lessons Learned from the Development of the First FDA-Approved Gene Therapy Drug, Voretigene Neparvovec-rzyl. Cold Spring Harbor Perspectives in Medicine, 13(5), a041307. https://doi.org/10.1101/cshperspect.a041307

Vancouver

Bennett J, Maguire AM. Lessons Learned from the Development of the First FDA-Approved Gene Therapy Drug, Voretigene Neparvovec-rzyl. Cold Spring Harbor Perspectives in Medicine. 2023;13(5):a041307. doi:10.1101/cshperspect.a041307

BibTeX
@article{Bennett2023,
  author = {Bennett, Jean and Maguire, Albert M},
  title = {Lessons Learned from the Development of the First FDA-Approved Gene Therapy Drug, Voretigene Neparvovec-rzyl},
  journal = {Cold Spring Harbor Perspectives in Medicine},
  year = {2023},
  volume = {13},
  number = {5},
  pages = {a041307},
  doi = {10.1101/cshperspect.a041307}
}
Kostenlos starten →